Delivery Order SPE2DB20D1100-SPE2DB24FB6C0
- Not listed
- This federal contract award is for the delivery of Pfizer's COVID-19 vaccine over a period of 6 months to 4 years, under an Emergency Use Authorization. The $2,259.62 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract does not have a set-aside designation, indicating open competition. Amerisourcebergen has a significant Indefinite Delivery Contract...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division. The $2,138.52 firm fixed price delivery order is for the supply of Pfizer's COVID-19 vaccine for the 2023-2024 period, under the Emergency Use Authorization (EUA). The award is not set-aside, and is delivered under Amerisourcebergen's $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as the primary vehicle for the...
- This federal contract award, valued at $6,600.90, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a Delivery Order contract for the delivery of Pfizer COVID-19 vaccine doses during the 2024-2025 period, under the Emergency Use Authorization (EUA). The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a significant...
- This federal contract award, valued at $1,081.34, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution company. The contract is for the delivery of Pfizer COVID-19 vaccines, under an Emergency Use Authorization (EUA), with an ultimate completion date of March 13, 2024. Amerisourcebergen Drug Corp holds an Indefinite Delivery Contract (IDC) with DLA, valued up to...
- This is a delivery order award to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The $1,525.97 firm-fixed-price contract is for the supply of the Pfizer COVID-19 vaccine under the Emergency Use Authorization (EUA) for the 2023-2024 period, with an ultimate completion date of April 22, 2024. Amerisourcebergen holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical to...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distribution company Amerisourcebergen Corporation. The contract, a $1,081.34 firm fixed price delivery order, is for the provision of Pfizer COVID-19 vaccine doses in the 6-month to 4-year dosage form under the Emergency Use Authorization (EUA). The contract has a completion date of January 31, 2024. Amerisourcebergen Drug Corp, as the prime...
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of 0.9ML doses of the Pfizer COVID-19 vaccine under an Emergency Use Authorization (EUA) from April 2023 to April 2024. The $1,525.97 firm fixed-price delivery order was issued by the Defense Logistics Agency (DLA) Troop Support Medical, a component of the Department of Defense. Amerisourcebergen holds an Indefinite Delivery Contract (IDC) with the DLA valued up to $999,999,999.00 through...
- This federal contract award is for the delivery of Pfizer COVID-19 vaccine doses to the Defense Logistics Agency (DLA) Troop Support Medical. The $1,642.75 firm-fixed-price delivery order was awarded to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, on October 22, 2024. The contract has an ultimate completion date of November 13, 2024 and does not have a set-aside designation. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp's Corporate Office division. The $3,207.75 award is for the supply of Pfizer COVID-19 vaccines under Emergency Use Authorization (EUA) from May 2023 to May 2024. Amerisourcebergen, a major pharmaceutical distribution company, has an Indefinite Delivery Contract (IDC) worth up to $999,999,999.00 with DLA Troop Support Medical to provide a comprehensive range...
- This federal contract award is a delivery order worth $1,642.75 issued to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The award is for the provision of Pfizer COVID-19 vaccines between 2024-2025, with an ultimate completion date of November 7, 2024. The contract is a firm fixed-price arrangement with no set-aside designation, indicating open competition. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB24FB6C0Delivery Order
This federal contract award is for the delivery of Pfizer's COVID-19 vaccine under an Emergency Use Authorization (EUA) for a 6-month to 4-year period, awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp's Corporate Office division. The $2,138.52 firm fixed-price delivery order has a completion date of May 6, 2024. AmerisourceBergen, a large pharmaceutical distribution company, holds a significant Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 with DLA Troop Support Medical through December 2025. This single-award IDC serves as the primary vehicle for AmerisourceBergen to deliver a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. The company also holds a smaller IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs, valued up to $750,000 through May 2024. This specific award was not set aside and was awarded on a full and open competition basis, highlighting AmerisourceBergen's competitive position in the federal pharmaceutical supply market.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.1k | 5/3/24 |